Maren Thurow Appointed as Head of Global Communications
Maren Thurow has officially stepped into the role of Vice President and Head of Global Communications at Grünenthal. In this significant position, she is taking over from Florian Dieckmann, who has been instrumental in developing the communications team since 2021. As the new head, Maren is set to oversee all communications efforts across various markets, working closely with the team headquartered in Aachen.
Strategic Impact of Leadership Change
This transition comes at a crucial time for Grünenthal as the company has experienced impressive financial success recently. The financial metrics showcase a remarkable growth trajectory, with adjusted EBITDA more than tripling since 2017. This growth has been supported by targeted acquisitions, notably the integration of Valinor Pharma and the launch of Movantik™ in July. As a pioneer in the pharmaceutical industry, Grünenthal is committed to advancing its research and development initiatives.
Further Development in Pharmaceutical Innovations
Grünenthal is making strides with its key research programs, progressing both the Glucocorticoid Receptor Modulator (GRM) and Nociceptin (NOP) Receptor Agonist programs into the subsequent stages of development. Alongside this, the company is maximizing its core products, Qutenza™ and its established brands, while also ensuring a seamless transition following the acquisition of Valinor Pharma. Future growth strategies include identifying additional strategic acquisition opportunities.
Maren's Background and Experience
Before taking on her new role at Grünenthal, Maren joined the organization in 2021 as Head of Global Commercial Communication. Her wealth of experience includes serving as Planning Director, where she contributed significantly to the commercial strategy. Previously, Maren held a senior leadership position at FleishmanHillard, a top global public relations firm known for its robust communications strategies.
Grünenthal's Commitment to Patients
Grünenthal is a leading player in the field of pain management. As an innovative, science-driven pharmaceutical company, its mission is to provide groundbreaking treatments and advanced technologies, ultimately improving lives worldwide. The team at Grünenthal channels its passion for innovation into realizing its vision of a world free of pain.
Global Presence and Employment
With its headquarters situated in Aachen and operations across 28 countries, Grünenthal's reach is extensive. The company has a footprint that spans Europe, Latin America, and the U.S., with its products available in approximately 100 nations. Achieving revenues of €1.8 billion in 2024 and employing around 4,300 people, Grünenthal continues to expand its global influence in the pharmaceutical sector.
Frequently Asked Questions
Who is Maren Thurow?
Maren Thurow is the new Vice President and Head of Global Communications at Grünenthal, succeeding Florian Dieckmann.
What are Maren Thurow's previous roles?
Before her new role, Maren served as Head of Global Commercial Communication and Planning Director at Grünenthal, among other positions in public relations.
What is Grünenthal's primary focus?
Grünenthal focuses on pain management and innovative treatments, aiming to improve patient lives through cutting-edge pharmaceuticals.
How has Grünenthal performed financially?
Grünenthal has seen a remarkable increase in adjusted EBITDA, more than tripling since 2017, thanks to strategic acquisitions and growth initiatives.
Where is Grünenthal located?
Grünenthal is headquartered in Aachen, but operates in 28 countries and has a significant global presence in the pharmaceutical industry.
